STABLE FORMULATION OF EFINACONAZOLE

Abstract

A new stable formulation comprising efinaconazole and its process for preparing. The formulation of the present invention exhibits low levels of impurities.

Claims

1. A formulation comprising efinaconazole, a volatile polar organic solvent, at least one phenolic antioxidant and an acidifying agent selected from monoprotic acids, diprotic acids, alpha-ketoglutaric acid, their pharmaceutically acceptable salts and mixtures thereof.

2. A formulation according to claim 1 further comprising at least one chelating agent selected from ethylenediamine and pharmaceutically acceptable salts thereof.

3. A formulation according to claim 1 comprising: a. efinaconazole, b. 45-85% volatile polar organic solvent c. 0.01-5% phenolic antioxidant d. an acidifying agent selected from monoprotic acids, diprotic acids, alpha-ketoglutaric acid, e. at least one chelating agent selected from ethylenediamine and pharmaceutically acceptable salts thereof. f. optionally, a co-solvent

4. A formulation according to any one of claims 1 wherein the volatile polar organic solvent selected from the group ethyl acetate, 1-propanol, isopropanol and acetone.

5. A formulation according to claim 1 wherein the volatile polar organic solvent is 45-85% ethyl acetate.

6. A formulation according to claim 1 to 5 wherein the phenolic antioxidant is butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), β, γ, δ-tocopherol, α-tocopherol (synthetic or natural form), 2,6-di-tert-butyl-4-ethylphenol, 2,4-di-tert-butylphenol, 2,6-di-tert-butylphenol or mixtures thereof.

7. A formulation according to claim 6 further comprising a phospholipid.

8. A formulation according to claim 6, further comprising a co-solvent selected from glycerol, polyethylene glycols (PEGs), polypropylene glycol, water and mixtures thereof.

9. A formulation according to claim 8, wherein the co-solvent is polypropylene glycol.

10. A process for preparing a formulation according to claims 1 to 9 comprising: i) Dissolving efinaconazole and the phenolic antioxidant in solvent and optionally co-solvent ii) Dissolving an acidifying agent selected from monoprotic acids, diprotic acids, alpha-ketoglutaric acid, their pharmaceutically acceptable salts and mixtures thereof and optionally a chelating agent in mixture of step i) or in water iii) Mixing solution or dispersion from step i) with the solution or dispersion of step ii).

11. A process for preparing a formulation according to claim 10 comprising: i) Dissolving efinaconazole and the phenolic antioxidant in ethyl acetate and optionally co-solvent ii) Dissolving a-ketoglutaric acid and a chelating agent in mixture of step i) or in water iii) Mixing solution or dispersion from step i) with the solution or dispersion of step ii).

Description

DETAILED DESCRIPTION OF THE INVENTION

[0037] The present invention relates to a new stable formulation comprising efinaconazole. In a first embodiment, the new formulation comprises efinaconazole, a volatile polar organic solvent, at least one phenolic antioxidant and an acidifying agent selected from monoprotic acids, diprotic acids, alpha-ketoglutaric acid, their pharmaceutically acceptable salts and mixtures thereof.

[0038] The term “stable” relates to a formulation capable of maintaining impurities profile below the ICH qualification thresholds, therefore acceptable stability with respect to the levels of impurities. Such stability is required for commercially relevant periods, for example about 6, 12, 18, or 24 months after manufacturing, during which times a product is stored in its original packaging at common ambient temperatures. Maintaining acceptable impurities level after opening is especially relevant for liquid or dispersions. Storage stability can be predicted by the impurity formation observed during storage for shorter times under “accelerated” stability testing conditions, such as at 40° C. and 75% relative humidity for 6 months.

[0039] The present invention relates to a new formulation which exhibit appreciable chemical storage stability. The embodiments exhibit pharmaceutically acceptable impurities profile below the ICH qualification thresholds, during accelerated stability testing. Some embodiments exhibit lower total impurities levels than the product used as reference product, marketed as Jublia® solution in USA.

[0040] The present formulation exhibit low total impurities level.

[0041] The term “efinaconazole” in the context of the present invention, refers to (2R ,3R)-2-and pharmaceutically acceptable salts thereof.

[0042] A chelating agent is a substance whose molecules can form several bonds to a single metal ion. A chelating agent is a multidentate ligand. Three widely used chelating agents are ethylenediamine, ethylenediaminetetraacetic acid and dimercaprol. According to the invention the chelating agent is selected from ethylenediamine, its pharmaceutically acceptable salts and mixtures thereof. Preferably ethylenediamine is used in some embodiments.

[0043] The term “antioxidants” in the context of the present invention, is compounds which scavenge free radicals by donating hydrogen to them, and they produce relatively stable antioxidant radicals with low standard reduction potential. Antioxidants slow down the oxidation rates by a combination of scavenging free radicals, chelating pro-oxidative metals, quenching singlet oxygen and photosensitizers. The higher stability of antioxidant radicals than the radicals in the finished product, is due to resonance delocalization throughout the phenolic ring structure. Preferably the bond dissociation energy for O—H of phenolic antioxidants is less than 80 kcal/mol. In a preferred embodiment the phenolic antioxidants are tocopherols, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), 2,6-di-tert-butyl-4-ethylphenol, 2,4-di-tert-butylphenol, 2,6-di-tert-butylphenol, tert-butylhydroquinone (TBHQ), propyl gallate (PG), lignans, flavonoids, and phenolic acids, ubiquinone (coenzyme Q), carotenoids, citric acid, amino acids and mixtures thereof. In a further preferred embodiment butylated hydroxytoluene (BHT), β, γ, δ-tocopherol, a-α-tocopherol (synthetic or natural form), 2,6-di-tert-butyl-4-ethylphenol, 2,4-di-tert-butylphenol, 2,6-di-tert-butylphenol and mixtures thereof are used.

[0044] The term “pharmaceutical acidifying agent” in the context of the present invention, is compounds which can create an acidic pH microenvironment within the formulation and therefore increase formulation stability. Preferably, the acidifying agent used are selected from monoprotic acids, diprotic acids and a-ketoglutaric acid. Their pharmaceutically accepted salts thereof can be also used. More preferably a-ketoglutaric acid is used. Monoprotic acids are those acids that are able to donate one proton per molecule during the process of dissociation (sometimes called ionization). Non-limiting examples of Zo monoprotic acids are hydrochloric acid (HCl), formic acid (HCOOH), acetic acid (CH.sub.3COOH), nitric acid (HNO.sub.3), benzoic acid (C.sub.6H.sub.5COOH), boric acid (H.sub.3BO.sub.3) and N-acetyl cysteine (NAC). Diprotic acids can donate two protons per acid molecule, in contrast to monoprotic acids that only donate one proton per molecule. Non-limiting examples of diprotic acids are succinic acid (CH.sub.2).sub.2(CO.sub.2H).sub.2, uric acid (C.sub.5H.sub.4N.sub.4O.sub.3), sulfuric acid (H.sub.2SO.sub.4), carbonic acid (H.sub.2CO.sub.3), oxalic acid (HOOCCOOH). Triprotic acids are able to donate three protons per acid molecule, in contrast to monoprotic acids that only donate one proton per molecule etc.

[0045] The present formulations are suitable to comprise at least one phospholipid, preferably phosphatidylcholine, more preferably at a concentration of 0.01 to about 10.0% (w/v).

[0046] Polar solvents decrease the radical scavenging activity of the antioxidants due to the intermolecular hydrogen bonding between oxygen or nitrogen in a polar solvent and OH group in phenolic antioxidants. Suitable pharmaceutically accepted volatile polar organic solvents are liquids such as esters, alcohols, ketones and saturated hydrocarbons with a high vapor pressure (greater than about 2 kPa at 20° C.) and boiling point less than about 100° C. at atmospheric pressure. Examples of suitable volatile polar organic solvents are ethyl acetate, butyl acetate, methyl acetate, 1-propanol, isopropanol (isopropyl alcohol), ethanol, acetone, methyl ethyl ketone and methyl isobutyl ketone. In a preferred embodiment the pharmaceutically accepted volatile polar organic solvents is chosen from ethyl acetate, 1-propanol, isopropanol, acetone and mixtures thereof. In a preferred embodiment the pharmaceutically accepted volatile polar organic solvents is ethyl acetate.

[0047] Co-solvents such as Glycerol, Polyethylene Glycols (PEGs), Propylene Glycol, Polypropylene Glycols, (PPGs), water and mixtures thereof, can be used. In a preferred embodiment Polypropylene Glycols (PPGs), water and mixtures thereof can be used.

[0048] In certain embodiments, the composition of the invention is free of volatile siloxanes. Siloxanes, also known as silicones, are cyclic and/or linear saturated cyclic and liner silicone-oxygen hydrides. Examples of cyclic siloxanes include polydimethylcyclosiloxanes, generally known as cyclomethicones (such as Zo cyclopentasiloxane, cyclotetrasiloxane, decylmethylcyclopentasiloxane, and the like). Examples of linear siloxanes include linear polysiloxanes (such as hexamethyldisiloxane, octamethyltrisiloxane, and the like).

[0049] In one embodiment the formulation comprises efinaconazole, [0050] a. 45-85% a volatile polar organic solvent [0051] b. 0.01-5% a phenolic antioxidant [0052] c. an acidifying agent selected from monoprotic acids, diprotic acids, alpha-ketoglutaric acid, their pharmaceutically acceptable salts and mixtures thereof. [0053] d. optionally, at least one chelating agent selected from ethylenediamine and pharmaceutically acceptable salts and mixtures thereof [0054] e. optionally, a co-solvent

[0055] In another embodiment the formulation comprises efinaconazole, [0056] a. 45-85% ethyl acetate [0057] b. 0.01-5% a phenolic antioxidant [0058] c. an acidifying agent selected from monoprotic acids, diprotic acids, alpha-ketoglutaric acid, their pharmaceutically acceptable salts and mixtures thereof. [0059] d. at least one chelating agent selected from ethylenediamine and pharmaceutically acceptable salts and mixtures thereof [0060] e. optionally, a co-solvent selected from the group glycerol, polyethylene glycols (PEGs), propylene glycol, polypropylene glycols (PPGs), water or mixtures thereof

[0061] In another embodiment the formulation comprises efinaconazole, [0062] a. 45-85% volatile polar organic solvent, from the group ethyl acetate, 1-propanol, isopropanol and acetone [0063] b. 0.01-5% phenolic antioxidant [0064] c. a-ketoglutaric acid [0065] d. ethylenediamine [0066] e. optionally, 0.01-10% of at least one phosphatidylcholine [0067] f. optionally, a co-solvent selected from the group glycerol, polyethylene glycols (PEGs), propylene glycol, polypropylene glycols (PPGs), water or mixtures thereof.

[0068] The term “reference product” refers to a currently or previously marketed efinaconazole solution, also described as the “originator” or “branded product” serving as a comparator in the studies. An “originator” or “branded” product are examples of a reference product. The preferred “reference product” is Jublia® solution marketed in USA.

EXAMPLES

[0069] The formulation as described herein may be illustrated by the following examples which are not to be construed as limiting the scope of the invention: The “reference product” is Jublia® 10% Efinaconazole solution marketed in USA. Examples 1-4, formulated as shown in Table 1, contained 10% efinaconazole by weight. Examples 1-4 may optionally contain phospholipids and preferably phosphatidylcholine. The concentration (w/w %) of phosphatidylcholine may vary from 0.01%-10.00% by making known adjustments. Examples 1-4 were prepared according to the general manufacturing process:

[0070] Step a: In the appropriate amount of ethyl acetate, dissolve efinaconazole, polypropylene glycol 2000 and δ-tocopherol (Example 1) or α-tocopherol (synthetic or natural form) (Example 2) or Butylated Hydroxyanisole (Example 3) or 2,6-di-tert-butyl-4-ethylphenol and/or 2,4-di-tert-butylphenol and/or 2,6-di-tert-butylphenol (Example 4).

[0071] Step b: In another vessel, dissolve ethylenediamine and α-ketoglutaric acid in the appropriate amount of water.

[0072] Step c: Mix both solutions obtained by step a and step b until a clear, yellowish solution forms.

[0073] Alternatively, and if water is not used, dissolve ethylenediamine and α-ketoglutaric acid in the solution of step a. Skip step c.

TABLE-US-00001 TABLE 1 Pharmaceutical topical composition of Examples 1, 2, 3 and 4 Example 1 Example 2 Example 3 Example 4 Ingredients (w/w %) (w/w %) (w/w %) (w/w %) Efinaconazole 10 10 10 10 Ethyl Acetate 45-85 45-85 45-85 45-85 δ-tocopherol 0.10-5.00 — — — (δ-Vitamin E) dl-α-tocopherol — 0.10-5.00 — — (Vitamin E, synthetic form) Butylated — — 0.10-2.00 — Hydroxyanisole (BHA) 2,6-di-tert-butyl-4- — — — 0.10-2.00 ethylphenol and/or 2,4-di-tert-butylphenol and/or 2,6-di-tert- butylphenol Optional:  0.10-10.00  0.10-10.00  0.10-10.00  0.10-10.00 Phosphatidylcholine (PC - Phospholipon 90 G) Polypropylene Glycol  5.00-30.00  5.00-30.00  5.00-30.00  5.00-30.00 Mw 2000 (PPG 2000) Ethylenediamine 0.00001-0.01   0.00001-0.01   0.00001-0.01   0.00001-0.01   (EDA) α-ketoglutaric acid 0.001-0.10  0.001-0.10  0.001-0.10  0.001-0.10  Water, purified 0-5 0-5 0-5 0-5

[0074] Comparative stability results are summarized in Table 2. The results after analysis for total impurity content of tested products: Reference product, Example 1, Example 2, Example 3 and Example 4 after 0, 3 and 6 months in accelerated conditions (40° C.±2° C., 75%±5% RH) are presented in the table below: Impurity results after 0, 3 and 6 months in accelerated conditions (40° C.±2° C., 75%±5% RH) Total impurities are acceptable since they are all below the ICH qualification thresholds. The reference product used in the comparative study is Jublia® marketed in USA.

TABLE-US-00002 TABLE 2 Comparative stability results Storage Reference Conditions product Example 1 Example 2 Example 3 Example 4 Accelerated Total Total Total Total Total Conditions Impurities Impurities Impurities Impurities Impurities at 40° C./ 75% RH t = 0 0.00% 0.00% 0.00% 0.00% 0.00% 3 Months 0.16% 0.04% 0.14% 0.00% 0.04% 6 Months 0.23% 0.03% 0.33% 0.06% 0.09%

Stability Tests Methods:

[0075] Impurity tests were determined by HPLC, using the below analytical method:

[0076] Column: Restek Roc C18 (150 mm×4.6 mm, 5 μm); injection volume: 25 μL; wavelength: UV, 260 nm; flow: 1 mL/min, column temperature: 30° C.

[0077] Buffer: 3.15 g of ammonium formate salt were dissolved in 1 L of water. pH adjusted to 4.5 with concentrated formic acid.

[0078] Mobile phase A: 100% Buffer

[0079] Mobile phase B: 100% Acetonitrile

TABLE-US-00003 Time (min) MP A MP B 0 75 25 1.00 75 25 24.00 35 65 40.00 35 65 40.50 75 25 45.00 75 25

[0080] The diluent used for the samples' preparation is a 50:50 (v/v) solution of water:acetonitrile.

[0081] Thus, it should be appreciated that contemplated formulations will typically allow storage of the efinaconazole at least 6 months (and even longer) after first use without significant degradation of the efinaconazole. Efinaconazole may therefore be formulated for administration to human and various animals, and especially mammals. For example, formulations are suitable to be applied on the skin and the nail of mammals.